Vitamin K Study for Thinking and Memory in Coronary Heart Disease
Tests vitamin K against a placebo in adults over 60 with coronary heart disease.
Plain-language title generated from the registry record
Registry title: Vitamin K and Cognition in Coronary Heart Disease (NutriCog)
Key facts
- Where
- Montreal, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men and women aged 60 or older with stable coronary heart disease, to test whether vitamin K supplements help thinking skills and blood vessel function.
- Age
- 60 years and older
- Sex
- Men and women
- Disease stage
- Medically documented stable coronary heart disease
- Earlier treatment
- Cannot be taking vitamin K supplements (K1 or K2) or other cognitive aids. Daily dietary phylloquinone intake must be under 150 mcg.
Main reasons for not taking part
- Acute coronary syndrome or heart revascularization in the last 3 months
- Known left ventricular dysfunction (LVEF < 40%) or chronic heart failure
- Warfarin (Coumadin) use
- Cognitive impairment, depression or uncontrolled anxiety
- Malabsorption disorder such as advanced liver disease or Crohn's disease
Read by machine on 9 November 2026.
Where in Canada
- Montreal Heart InstituteMontreal, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Montreal Heart Institute
- Trial code
- NCT06855953
- Record updated
- 4 March 2025
- Original description
The purpose of this pilot study is to obtain a preliminary assessment of the effect of VK supplementation on cognitive performance and vascular function in adults with stable Coronary Heart Disease (CHD)Read full original descriptionShow less
Vitamin K Supplementation to Improve Cognition of Patients With Coronary Heart Disease: a Randomized Controlled Pilot Study
The purpose of this pilot study is to obtain a preliminary assessment of the effect of VK supplementation on cognitive performance and vascular function in adults with stable Coronary Heart Disease (CHD)
Inclusion: Men and women; Age 60 years and older; Medically documented stable Coronary Heart Disease (CHD); Daily dietary intakes of phylloquinone <150 mcg; Non-consumption of vitamin K supplements (i.e. K1 or K2, singly or in combination with other nutrients), or other cognitive aids; Good French or English understanding; Physical exercise not exceeding 2.5 hours/week of moderate to vigorous aerobic activity; Capacity and willingness to sign informed consent.
Exclusion: Recent modification of medication (<2 weeks); Recent acute coronary syndrome (<3 months) or recent coronary revascularization (bypass surgery or percutaneous coronary intervention, <3 months); Cognitive impairment (based on telephone version of the Mini-Mental State Examination test, score <19/23); Malabsorption disorder (advanced liver disease, Crohn's disease); Known left ventricular dysfunction (LVEF < 40%) or chronic heart failure; Warfarin (Coumadin) use; Diagnosis of depression or uncontrolled anxiety; Patient with auditory or vision impairments not properly corrected by glasses or hearing aids; Unable to read the informed consent form or unable to understand the oral explanations provided by the assessor.